Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Accumulated Expenses: 2016-2025

Historic Accumulated Expenses for Ultragenyx Pharmaceutical (RARE) over the last 10 years, with Sep 2025 value amounting to $220.5 million.

  • Ultragenyx Pharmaceutical's Accumulated Expenses rose 19.19% to $220.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $220.5 million, marking a year-over-year increase of 19.19%. This contributed to the annual value of $241.0 million for FY2024, which is 22.64% up from last year.
  • Ultragenyx Pharmaceutical's Accumulated Expenses amounted to $220.5 million in Q3 2025, which was up 21.98% from $180.8 million recorded in Q2 2025.
  • Ultragenyx Pharmaceutical's 5-year Accumulated Expenses high stood at $241.0 million for Q4 2024, and its period low was $82.7 million during Q1 2021.
  • Moreover, its 3-year median value for Accumulated Expenses was $178.6 million (2023), whereas its average is $181.0 million.
  • Per our database at Business Quant, Ultragenyx Pharmaceutical's Accumulated Expenses surged by 87.08% in 2022 and then fell by 7.89% in 2024.
  • Quarterly analysis of 5 years shows Ultragenyx Pharmaceutical's Accumulated Expenses stood at $145.6 million in 2021, then spiked by 40.62% to $204.7 million in 2022, then dropped by 4.00% to $196.5 million in 2023, then climbed by 22.64% to $241.0 million in 2024, then rose by 19.19% to $220.5 million in 2025.
  • Its Accumulated Expenses was $220.5 million in Q3 2025, compared to $180.8 million in Q2 2025 and $173.0 million in Q1 2025.